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Abstract
Background: Premedication before neonatal intubation is heterogeneous and contentious. The combination of a
short acting, rapid onset opioid with a muscle relaxant is considered suitable by many experts. The purpose of this
study was to describe the tolerance and conditions of intubation following anaesthesia with atropine, sufentanil
and atracurium in very premature infants.
Methods: Monocentric, prospective observational study in premature infants born before 32 weeks of gestational
age, hospitalised in the NICU and requiring semi-urgent or elective intubation. Intubation conditions, heart rate,
pulse oxymetry (SpO2), arterial blood pressure and transcutaneous PCO2 (TcPCO2) were collected in real time during
30 minutes following the first drug injection. Repeated physiological measurements were analysed using mixed
linear models.
Results: Thirty five intubations were performed in 24 infants with a median post conceptional age of 27.6 weeks
and a median weight of 850 g at the time of intubation. The first attempt was successful in 74% and was similar
for junior (75%) and senior (74%) operators. The operator rated conditions as “excellent” or “good” in 94% of
intubations. A persistent increase in TcPCO2 as compared to baseline was observed whereas other vital
parameters showed no significant variations 5, 10, 15 and 30 minutes after the first drug injection. Eighteen
(51%) desaturations (SpO2 less than or equal to 80% for more than 60 seconds) and 2 (6%) bradycardia (heart rate
less than100 bpm for more than 60 seconds) were observed.
Conclusion: This drug combination offers satisfactory success rate for first attempt and intubation conditions for the
operator without any significant change in heart rate and blood pressure for the patient. However it is
associated with frequent desaturations and a possible persistent hypercapnia. SpO2 and PCO2 can be significantly
modified during neonatal intubation and should be cautiously followed in this high-risk population.
Keywords: Endotracheal intubation, Newborn, Opioids, Muscle relaxant, Pain, Hypercapnia
Background
Endotracheal intubation is a frequent procedure in the
Neonatal Intensive Care Unit (NICU). Although neonatal
awake intubation is not recommended, except for emer-
gency situations, no consensus exists to date supporting
the use of a drug or a drug combination in neonates [1].
Clinical studies addressing premedication before endo-
tracheal intubation in neonates include randomised, con-
trolled trials vs placebo [2,3] or comparison of different
regimens [4-7] and observational studies [8-12]. Based on
these, experts have recommended the use of a short onset
opioid [1,13,14]. Fentanyl is the most studied synthetic
opioid in this context [6,8,9,11]. In contrast with the
scarce data regarding sufentanil use in neonates [15] and
the latest expert recommendations [1], French neonatolo-
gists use sufentanil more frequently than fentanyl for in-
tubating neonates either in the NICU [16] or in the
* Correspondence: xavier.durrmeyer@chicreteil.fr
1Epidemiology and Biostatistics Centre, Obstetrical, Perinatal and Pediatric
Epidemiology Team, Université Pierre et Marie Curie Paris VI, Paris, Inserm
UMRS 1153, France
2NICU, Centre Hospitalier Intercommunal, Créteil, France
Full list of author information is available at the end of the article
© 2014 Durrmeyer et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Durrmeyer et al. BMC Pediatrics 2014, 14:120
http://www.biomedcentral.com/1471-2431/14/120
delivery room [17]. An increase in sufentanil use in
German NICUs has also been recently reported [18].
Some trials have demonstrated the interest of associating
a short onset opioid with a muscle relaxant [4,6,11,19].
However muscle relaxants are rarely used in France
[16,17,20]. Randomised controlled trials (RCT) usually
provide reliable evidence. However, real practice does
not always correspond to bedside conditions [16]. As
such, observational studies are frequently beneficial in
providing data from actual clinical practice [21,22].
The latter studies are necessary to objectively evaluate
the consequences of actual practices. In February 2007,
we implemented and prospectively evaluated a protocol in
our NICU for anaesthesia before endotracheal intubation
in non-life threatening situations combining atropine,
sufentanil and atracurium. This protocol was elaborated in
collaboration with the paediatric anaesthesiologists from our
institution and written after a review of the existing pub-
lished evidence at that time. Our objectives were to describe
the real conditions of the procedure, to document tolerance
and to collect adverse events in a group of premature infants
born under 32 weeks of gestational age (GA).
Methods
Anaesthesia protocol
Infants received intravenously 15 μg/kg of atropine as a
bolus followed by 0.2 μg/kg of sufentanil over 60 seconds
and 0.3 mg/kg of atracurium over 30 seconds. If paraly-
sis was not obtained within 2 minutes after atracurium
injection, an additional dose of 0.1 mg/kg could be given
and repeated once (maximal atracurium cumulative dose
0.5 mg/kg).
Intubation procedure
In non intubated patients, a bag-valve-mask ventilation
(Ambu© Mark IV baby, Denmark), without positive ex-
piratory pressure, was performed from the beginning of
atropine injection. In intubated patients who needed an
endotracheal tube (ETT) change, the ETT was removed
once the new ETT had been introduced in the opposite
nostril and the laryngoscope was inserted. FiO2 was set
at the discretion of the operator and no target SpO2 nor
minimal duration of preoxygenation was recommended
due to uncertainty on optimal preoxygenation in this
population [23]. When a junior operator performed the
procedure, a senior operator was always present to take
over the procedure in case of failure. A maximum of
two attempts were allowed for junior operators. Intub-
ation in our unit was always nasotracheal and performed
using an appropriate sized Macgill forceps.
Data collection
This observational study was conducted in a single level
3 unit between February and August 2007. Data were
collected prospectively on a standardised form by an ob-
server who was not involved in the procedure (resident,
nurse, fellow or consultant). Patients’ clinical characteristics
were collected from his/her chart and included gestational
age at birth, birth weight, sex, postnatal age, corrected age
and weight at the time of intubation, main indication for
intubation and opioid or benzodiazepine administration
within the 24 hours prior to the intubation.
Intubation procedure
The duration of the procedure was defined as the time
between first laryngoscope insertion and definitive
tube fixation to the nose with a tape. Each laryngo-
scope insertion was considered as an attempt. Fellows
and consultants were considered as senior operators
and residents as junior operators. Once intubated, in-
fants were ventilated with a pressure-limited ventilator
(Babylog 8000, Dräger, Lubeck, Germany). Ventilator
settings were collected 1 minute before the first drug
injection (baseline = M-1), then at 5, 10, 15 and 30 mi-
nutes after first drug injection (referred as M5, M10,
M5 and M30).
Vital signs collection
Heart rate, pulse oxymetry and non invasive blood pres-
sure (Viridia, Philips Medical Systems, Andover, MA)
were continuously monitored and values were collected
1 minute before the first drug injection (baseline =M-1),
then at 5, 10, 15 and 30 minutes after first drug injection
(referred as M5, M10, M5 and M30). The lowest heart
rate and pulse oxymetry values during the intubation
procedure were collected. Whenever possible and avail-
able, transcutaneous CO2 partial pressure (TcPCO2)
(Intellivue TcG10, Philips Medical Systems, Andover,
MA) was continuously recorded and collected at the
previously specified time points.
Quality of sedation
Data regarding the quality of intubation conditions were
collected immediately after completion of the procedure
by the operator who succeeded the intubation according
to the following scale adapted from Hans [24] and
Cooper [25]:
– Excellent: Relaxed jaw and open vocal cords and no
movement when inserting ETT
– Good: Relaxed jaw and open vocal cords and mild
movements when inserting ETT
– Acceptable: Mild jaw contraction and/or moving
vocal cords and/or cough when inserting ETT
– Poor: Jaw contraction or closed vocal cords or
intense cough or rigidity when inserting ETT.
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Adverse events
Expected adverse events included:
– Thoracic rigidity diagnosed by the operator without
any specific predefined criteria.
– Desaturation arbitrarily defined as a SpO2 value ≤ 80%
for more than 60 consecutive seconds. Duration was
measured with a stopwatch.
– Bradycardia defined as heart rate < 100 bpm lasting
more than 60 seconds. This was obtained from a
posteriori monitoring recordings analysis.
– Upper airway injury defined as presence of blood in
the mouth during or after the procedure.
Any other adverse events could be recorded freely on
the data collection form.
Statistical analysis
Data reporting
Descriptive statistics were expressed as median or mean
according to their distribution. Intubation conditions and
incidence of desaturations were compared between junior
and senior operators using Fisher’s exact test or Mann–
Whitney U test.
Predictive model
We used mixed linear models in order to predict the
changes in heart rate, pulse oxymetry, mean arterial blood
pressure (MAP) and TcPCO2 over time based on our ob-
servations. Changes in the parameters were modeled using
fractional polynomials in order to take into account non-
linear time trends. In order to ensure independent obser-
vations, only the first episode of intubation was considered
for the building of these models if multiple intubations
were performed in the same infant at different time
points.
A p value below 0.05 was considered significant. All
analyses were performed using Stata v11.2 software
(Statacorp, Texas, USA).
Ethics
No other consent than consent to usual standard care
from the parents was requested since the implementa-
tion of the protocol was part of a standard of care modi-
fication process. The local ethics committee (groupe de
reflexion éthique de l’Hôpital Intercommunal de Créteil)




Between February and August 2007, we collected data
on 35 intubations in 24 infants born under 32 weeks of
gestational age. Studied infants (13 boys, 11 girls) had a
median (range) gestational age at birth and birth weight
of 26.0 (23.9-31.6) weeks and 850 (480–1860) g, re-
spectively. During the study period 17 infants underwent
one intubation, 3 infants 2 intubations and 4 infants 3
intubations.
Intubation conditions
All studied intubations were semi-urgent or planned in-
tubations. Their conditions are summarized in Table 1.
First attempt was successful in 74% and conditions were
considered “excellent” or “good” by operators in 94% of
intubations according to our 4-level quality of sedation
assessment. One infant required an additional 0.1 mg/kg
dose of atracurium (cumulated dose 0.4 mg/kg) and 3
infants required 2 additional 0.1 mg/kg doses of atracur-
ium (cumulated dose 0.5 mg/kg). No drug or dosing
error was observed. Mean +/− SE (time points) delta
pressures (i.e. peak inspiratory pressure - PEEP) for infants
who were receiving invasive ventilation were 14.0 +/− 3.2
(M5), 13.2+/− 2.3 (M10), 13.3 +/− 2.7 (M15) and 13.1 +/−
2.4 (M30) cm H2O. Mean +/− SE (time points) set respira-
tory rates were 68.7 +/− 9.8 (M5), 67.3 +/− 9.7 (M10),
70.9 +/− 9.4 (M15), 71.9 +/− 9.6 (M30) cycles/minute.
Vital signs
Figure 1a-1d illustrate absolute changes from baseline
over time in heart rate, pulse oxymetry, MAP and
TcPCO2, respectively. Heart rate, pulse oxymetry and
MAP values collected at specified time points remained
relatively stable as compared to baseline (Figure 1a, 1b,
1c). TcPCO2 values generally increased from baseline al-
though they tented to be more dispersed over time
(Figure 1d).
Adverse events
A desaturation ≤ 80% lasting > 60 seconds was observed
in 18 intubations (51%) (Table 1). During the 35 ana-
lysed intubations, we observed 2 bradycardias < 100 bpm
lasting longer than 60 seconds, 3 traumatic injuries of
upper airways and 8 chest-wall rigidities. In all cases of re-
ported chest-wall rigidity but one, a prolonged desatur-
ation was observed. No other adverse event was reported.
Experience of the operator
A junior and a senior operator carried out the first at-
tempt for intubation in 12 and 23 intubations respectively.
Infants’ median GA at birth, birth weight, post concep-
tional age at intubation, age at intubation and weight
at intubation were comparable for junior and senior
operators. First intubation attempts were successful for
75% and 74% of junior and senior operators respect-
ively (p = 1.00). Median durations of intubation were
199 and 165 s. for junior and senior operators respect-
ively (p = 0.90). The frequencies of desaturations < 80%
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lasting > 60 s. were 42% and 57% for junior and senior
operators respectively (p = 0.49).
Predictive model
Predicted heart rate, pulse oxymetry, MAP and TcPCO2
over time using mixed linear models are illustrated in
Figure 2a-2d respectively. We found no statistically sig-
nificant time trends for heart rate, pulse oxymetry and
mean arterial blood pressure whereas TcPCO2 changed
significantly over time (p < 0.001).
Discussion
This observational study showed that in very premature
infants the association of atropine, sufentanil and atra-
curium provided good intubation conditions as rated by
the operator and a 74% success rate for first attempt. No
significant changes in heart rate, mean arterial blood
pressure or pulse oxymetry recorded at predefined time
points were observed. Desaturations below 80% lasting
for more than 60 consecutive seconds were however fre-
quent (51%) and a significant increase in TcPCO2 was
observed within the 30 minutes following the first drug
injection.
The use of atropine before endotracheal intubation is
controversial [1,26]. In a recent observational study, 25%
of neonates undergoing tracheal intubation in level 3
units experienced bradycardia between 100 and 60 bpm
and 21% experienced bradycardia < 60 bpm [27]. In this
study atropine use decreased the frequency of bradycardia
between 100 and 60 bpm, but not the frequency of brady-
cradia < 60 bpm. In addition recent results are reassuring
regarding atropine use in neonates [28]. Considering these
observations and the significance of vagal tone in prema-
ture infants [29] we still include atropine as part of our
premedication before endotracheal intubation although
strong supporting evidence is still lacking.
Opioids have been the most studied drugs for neonatal
intubation, either alone or combined to a muscle relax-
ant [2,4-6,8,9,11,19]. The use of morphine is arguable
because of its delayed onset of action [1] and studies
showing that it may be less effective than other drug
regimens for intubating neonates [5,7]. Rapid onset,
short acting opioids used as anaesthetics for tracheal in-
tubation include alfentanil, fentanyl, sufentanil and remi-
fentanil. Sufentanil has shown a faster elimination and a
shorter site effect than fentanyl in some circumstances
[30]. Thus, it could be the preferred drug in premature
infants who usually have altered elimination capacities.
Since some recent European studies have reported a fre-
quent use of sufentanil in preterm neonates [16,17] or a
trend to increasing its use [18], we consider that data on
tolerance and safety are necessary. Remifentanil also
seems to be a promising opioid for tracheal intubation
either alone [10] or in association with other drugs [5].
Nonetheless, one of its drawbacks is the difficulty to de-
termine its appropriate dose [31].
In 6 other studies associating a synthetic opioid with a
muscle relaxant, the first attempt success rate was below
74% (range 35% to 67%) in 4 studies [4,9,11,19] and over
74% (77% and 90%) in 2 studies [2,8]. In a recently pub-
lished observational study, the overall success rate for the
first intubation attempt in neonates across 5 academic
Table 1 Condition of 35 intubations in infants < 32 weeks GA
Condition Results
Median post natal age at intubation in days [IQR] 10 [4-16]
Median post conceptional age at intubation
in weeks [IQR]
27.6 [26.3-28.9]
Median weight at the time of intubation in g [IQR] 850 [740-1000]
Ventilatory support at the time of intubation, n (%)
Invasive ventilation 10 (28.5%)
Non-invasive ventilation 23 (66%)
Spontaneous breathing 2 (5.5%)




Indication for intubation, n (%)
Respiratory failure 12 (34%)
Apnea 10 (28.5%)
ETT change 10 (28.5%)
Surgery 3 (9%)
Median FiO2 one minute before atropine
injection, % [IQR]
37 [24-60]






Median duration of intubationa, s [IQR] 180 [110-328]





Desaturation <80%, > 60 seconds, n (%) 18 (51%)
Bradycardia < 100 bpm, > 60 seconds, n (%) 2 (6%)
Median lowest saturation, % [IQR] 58 [48-79]
Median lowest heart rate, bpm [IQR] 141 [120-157]
aTime between the first laryngoscope insertion and definitive tube fixation to
the nose with a tape.
IQR: Interquartile range.
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level III centres was 44% [32]. For residents, this rate fell
to 20.3%. We consider that the rate we observed in our
study is rather high, especially among junior operators.
The observed success rate of first attempt in a population
where 75% of infants had a weight below 1000 g at the
time of intubation could be explained, at least partially, by
the satisfactory conditions for upper airway visualization
as assessed by the operator using the quality of sedation
scale. Studies exploring the combination of a fast acting
opioid and a muscle relaxant found that experienced
personnel had a higher success rate than inexperienced
personnel [8,11]. We did not find this difference. This
could be explained by a lack of power so we cannot con-
clude on the efficacy of our regimen on this outcome.
Saturation values ≤ 80% were frequently observed in
other studies although usually of shorter duration than
in ours [9,11,27]. It should be noted that 99% of infants
in Venkatesh et al.’s study [27] and all infants in Lemyre
et al.’s study [11] were preoxygenated with 100% FiO2.
Dempsey et al. [9] recommended to obtain a saturation
of at least 95% before starting the procedure. In our
study the median FiO2 and the median SpO2 values one
minute before the first drug injection were respectively
37% and 94%. The absence of systematic preoxygenation,
of target SpO2 recommendation and of positive end-
expiratory pressure on our ventilation bags may explain
the high incidence of desaturations in our patients. This
advocates for proper positive end expiratory pressure
use and preoxygenation in very low birth weight infants
who are known to have reduced residual functional cap-
acity as compared to older infants [23]. This is probably
even more critical when a muscle relaxant is used result-
ing in additional lung derecruitment. On the other end,
oxygen toxicity for the developing eye, brain and lung
has been documented [33] and the risk/benefit ratio of
preoxygenation on long-term outcome is unknown.
Based on our experience, we believe that preoxygenation
performed through a face-mask connected to the ventilator
Figure 1 Absolute changes from baseline (median, IQR, extremes) in heart rate (a), SpO2 (b), mean arterial blood pressure (c) and
TcPCO2 (d) at observed time points. X axis (time points): M-1: one minute before atropine injection, M5: 5 minutes after atropine injection,
M10: 10 minutes after atropine injection, M15: 15 minutes after atropine injection, M30: 30 minutes after atropine injection. Y axis: Numerical
difference from baseline value for each parameter. Boxes represent values between the 1st and the 3rd quartile. The bar inside the box denotes
median value. The adjacent values are the most extreme values within 1.5 inter-quartile range of the nearer quartile. Black dots are outliers
outside adjacent values. Numbers in parenthesis denote the number of available measures at each time point. HR: heart rate, MAP: mean arterial
blood pressure.
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circuit should be used so that an effective positive end-
expiratory pressure can be provided and peak inspiratory
pressure can be controlled; we also believe that a target
SpO2 value of 95% should be aimed for.
The initial (M5) increase in TcPCO2 we observed is
probably due to the laryngoscopy during which no re-
spiratory movement exists due to muscle relaxant use.
However we were surprised to observe the persistence
of hypercapnia 10, 15 and 30 minutes after the first drug
injection. Possible explanations for this may include a
major derecruitment at the time of laryngoscopy result-
ing in collapsed compliance once mechanical ventilation
is started or resumed, inappropriate ventilator settings
after intubation and/or excessive permissive hypercapnia
as illustrated by the similar values observed at the differ-
ent time points for delta pressure and for respiratory
rate. Another possible explanation is a decrease in periph-
eral perfusion (especially cutaneous) in spite of maintained
central perfusion as illustrated by stable blood pressures,
resulting in an unreliable transcutaneous PCO2 measurement.
Unfortunately no arterial blood gas was sampled at that
time to confirm or not this hypothesis. Since no other
study explored variations in TcPCO2 or PCO2 during very
preterm infants’ intubation we might just have observed a
phenomenon that was so far ignored. Future studies
should explore gas exchange in the immediate period fol-
lowing intubation.
Thoracic rigidity could possibly be reduced by the in-
jection of the muscle relaxant before the opioid. This se-
quence can be controversial since paralysis prior to
anaesthesia may not be appropriate [34]. However, sev-
eral publications have reported the injection of a muscle
relaxant before an opioid [5,9] based on the hypothesis
that obtaining adequate paralysis before the peak opioid
effect appears might prevent thoracic rigidity. Therefore,
we currently inject atracurium before sufentanil in our
unit.
Sedatives such as midazolam or propofol are fre-
quently used as premedications for endotracheal intub-
ation [16,20-22]. Future studies should aim at comparing
Figure 2 Predictive models (mean, 95% CI) for the evolution of heart rate (a), SpO2 (b), mean arterial blood pressure (c) and TcPCO2
(d) over time. X axis: Time after first drug injection in minutes. Y axis: Polynomial of degree 2 predictive model for heart rate (a), pulse oxymetry
(b), mean arterial blood pressure (c) and TcPCO2 (d) changes over time. The solid black line illustrates estimated mean values for each studied
variable over time. The gray zone illustrates the 95% confidence interval for these estimated values.
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sedatives with the combination of an opioid and a
muscle relaxant. The monitoring of vital signs including
desaturations and PCO2 should be included in future
research.
Our study has several limitations. It is observational
and has no comparative group. The collection of data
was stopped after 7 months because caregivers were satis-
fied with this drug combination, this resulted in a limited
number of studied cases. We did not record the total
number of intubations performed during the study period.
Therefore we don’t know if the studied population is rep-
resentative of all very premature infants intubated in our
NICU. Especially we ignore if similar observations would
be obtained in emergency intubations. The median post-
natal age in our study was 10 days, which is older than the
age at intubation observed in other studies [5,10,21,22]. In
our unit premature infants born below 28 weeks GA re-
ceive prophylactic surfactant in the delivery room. Thus,
most intubations performed in very premature infants in
our NICU are re-intubations. This explains the age at in-
tubation in our population. Our observations might then
not be extrapolated to recently born premature infants.
The use of a muscle relaxant precluded the use of any
pain scale since body movements or facial expression can-
not be evaluated during paralysis. Skin conductance might
have provided information on analgesic efficacy of our
regimen [35]. However, at the time of our study this tech-
nique was not widely in use and the presence of atropine,
an anticholinergic drug, in our regimen precluded the use
of skin conductance. We did not record time to spontan-
eous limb and chest movements’ recovery. This informa-
tion would have helped in the comparison with other
opioid plus muscle relaxant regimens. We did not either
record the time from decision to intubate to tube fixation
which is of interest in an emergency situation. Our defin-
ition of the duration of intubation procedure does not
provide the time of glottis exposure as others have re-
ported [22]. Interpretation of this parameter is therefore
difficult.
Conclusion
Although the combination of atropine, sufentanil and
atracurium for intubating very premature infants offers
good intubation conditions without any significant change
in patients’ heart rate and blood pressure, proper preoxy-
genation and alternative drugs to muscle relaxant avoiding
paralysis and subsequent lung derecruitment need to be
further explored in order to improve tolerance and condi-
tions of neonatal intubation.
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